p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer

Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has shown to be a promising strategy in cancer therapy, yet clinical response in many types of cancer, including prostate cancer (PCa), is limited. Tumor cells secrete PD-L1 through exosomes or splice variants, which has been de...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncogene 2020-05, Vol.39 (19), p.3939-3951
Hauptverfasser: Liu, Jinghui, He, Daheng, Cheng, Lijun, Huang, Changkun, Zhang, Yanquan, Rao, Xiongjian, Kong, Yifan, Li, Chaohao, Zhang, Zhuangzhuang, Liu, Jinpeng, Jones, Karrie, Napier, Dana, Lee, Eun Y., Wang, Chi, Liu, Xiaoqi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!